However, the company will use its DaneVest Tech Fund money to help support national sales of its Prevagen Brain Cell Protection dietary supplements, which are supposed to combat memory loss, it said in a press release.
Though it has yet to get its brain cell protection drug into Phase 1 trials, Quincy Bioscience is far from the typical young biotech on a shoestring budget. Not only does the company have an unusual technology, but its technology is being marketed as an over-the-counter dietary supplement.
So Quincy already has sales rolling in, and thanks to that revenue and about $5 million in angel funding, had grown to 43 employees by late July.
Reserve your seat now for MedCity CONVERGE, to be held July 9-10 in Philadelphia. Discover strategies, solutions and startups in healthcare innovation. Be a part of this gathering where the entire healthcare ecosystem converges.